摘要
目的观察瑞舒伐他汀对血脂正常的老年冠心病患者炎性指标、血脂水平及心功能的影响。方法将纳入研究的246例血脂正常的老年冠心病患者随机分为他汀1组(85例)、他汀2组(81例)和对照组(80例)。对照组仅给予常规西药治疗,他汀1组和2组在常规治疗基础上分别给予瑞舒伐他汀20 mg/d、10 mg/d治疗。治疗3月,观察3组炎症指标,包括超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6),血脂水平包括总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)以及心功能指标包括左室舒张末期容积(LVEDV)、左室射血分数(LVEF)、左室收缩末期容积(LVESV)和氨基末端脑钠肽前体(NT-pro BNP)的变化情况。结果治疗前3组上述指标差异无统计学意义(P>0.05)。治疗后,3组hsCRP、TNF-α、IL-6均明显下降(P<0.05);他汀1组和他汀2组TC、TG、LDL-C下降,HDL-C上升(P<0.05),对照组治疗前后无明显变化(P>0.05);3组LVEDV、LVESV、NT-pro BNP均下降,LVEF上升(P<0.05);治疗后,各指标组间两两比较,他汀1组和2组上述指标改善程度均优于对照组(P均<0.05),他汀1组和他汀2组比较,除HDL-C外,其余指标差异均有统计学意义(P均<0.05)。结论瑞舒伐他汀对血脂正常的老年冠心病患者有积极的作用,且大剂量(20 mg/d)作用优于小剂量(10 mg/d)。
Objective To observe the effect of rosuvastatin on inflammatory factors, blood lipid level and heart function in elderly patients with coronary heart disease showing normal blood lipids. Methods 246 cases of elderly patients with coronary heart disease showing normal blood lipids were randomly divided into rosuvastatin group 1 （85 cases）, rosuvastatin group 2 （81 cases） and control group （80 cases）. Control group was treated with routine treatment, and rosuvastatin group 1 was treated with rosuvastatin 20 mg/d, rosuvastatin group 2 was treated with rosuvastatin 10 mg/d at night on the basis of routine treatment. After 3 months of treatment, the changes of inflammatory factors, including high sensitivity C reactive protein （ hs-CRP ）, tumor necrosis factor-α（ TNF-α）, interleukin 6 （ IL-6）, blood lipid levels, including total cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholesterol（ LDL-C）, high density lipoprotein cholesterol （HDL-C） and heart function, including left ventricular end diastolic dimension （ LVEDV）, left ventricular ejection fraction （LVEF）, left ventricular end systolic volume （LVESV） and N-terminal pro brain natriuretic peptide （NT- proBNP） of the three groups were analyzed and compared. Results （1） After treatment, the levels of hs-CRP, TNF-α, IL-6 of three groups were significantly decreased （P〈0. 05）; The levels of TC, TG, LDL-C of rosuvastatin group 1 and rosuvastatin group 2 were decreased and the level of HDL-C was increased （ P〈0. 05）, while the above parameters showed no significant change in control group after treatment （ P〉 0. 05 ） ; LVEDV, LVESV , NT-proBNP of three groups were significantly decreased and LVEF were increased （P〈 0.05 ）. （2） After treatment, all the above parameters showed significant difference between 3 groups （P〈 0. 05 ）, and all the above parameters except HDL-C showed significant difference between rosuvastatin group 1 and rosuvastatin group 2 （P〈0. 05）. Conclusions Rosuvastatin plays an active role in treatment of elderly patients with coronary heart disease showing normal blood lipids, and high dose （ 20 mg/d） is better than low dose （ 10 mg/d）.
出处
《实用老年医学》
CAS
2016年第6期496-499,共4页
Practical Geriatrics
关键词
老年人
冠心病
瑞舒伐他汀
不同剂量
血脂正常
aged
coronary heart disease
rosuvastatin
different doses
normal blood lipids
